Clarus Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 4
Founded: Northbrook IL United States (2003)
Status: No NME R&D (2003)

Organization Overview

First Clinical Trial
2007
NCT02697188
First Marketed Drug
2019
testosterone (delatestryl)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Claris Biotherapeutics, Inc. | CLARUS | Clarus Therapeutics | Clarus Therapeutics, Inc. | CLARUS THERAPEUTICS INC

Active Ingredients

Marketed Drugs (1)

testosterone (delatestryl) (2019)

Drugs in Phase 4 Trials (1)

testosterone (delatestryl) (13 trials)

Drugs in Phase 2 Trials (2)

csb-001 (1 trial)

enzalutamide (xtandi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Eunuchism (Phase 1)

Hypogonadism (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial APIs: 3